FDA Guidance and Notices, April 2026: The FDA-CMS RAPID Pathway and Device Classification Rules
For regulatory and reimbursement teams alike, the April 2026 announcement to read is RAPID, a pathway FDA and the Centers for Medicare & Medicaid Services (CMS) unveiled on April 23 to connect FDA review of Breakthrough devices with Medicare coverage. For certain Class II and III Breakthrough devices, the agencies would agree on clinical evidence early in development so that a national coverage decision follows FDA authorization more quickly. When announced it was still a plan in preparation, expected to take effect on publication of a final notice.
On April 7, FDA opened the READI-Home Innovation Challenge for devices that help patients and caregivers at home after discharge and reduce readmissions. An April 20 draft addressed compliance policy for certain air-purifying respirators approved by the National Institute for Occupational Safety and Health (NIOSH). Ten classification rules also appeared in the Federal Register, among them an Alzheimer's disease pathology assessment test, a digital therapy device for amblyopia, and the reclassification of non-invasive bone growth stimulators.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles